Miltefosine (Impavido) - FDA-Approved Oral Medication for Leishmaniasis

The Only FDA-Approved Oral Treatment for Leishmaniasis

Leishmaniasis is a serious parasitic disease transmitted by sandflies — and for years, treatment meant painful injections. Miltefosine (Impavido) changed everything. As the first and only FDA-approved oral antileishmanial medication, it offers patients a highly effective, convenient alternative to traditional injectable therapies, with proven results across multiple forms of the disease.

How Miltefosine Works

Miltefosine is an alkylphosphocholine compound that disrupts the cell membranes and vital metabolic processes of Leishmania parasites. By targeting the parasite at a cellular level, it delivers high efficacy rates while being taken as a simple oral capsule — no injections, no hospital visits required.

What Miltefosine Treats

• Visceral leishmaniasis — the most severe form, affecting internal organs including the spleen, liver, and bone marrow
• Cutaneous leishmaniasis — skin lesions caused by Leishmania infection
• Mucosal leishmaniasis — affecting the mucous membranes of the nose, mouth, and throat

Why Choose Miltefosine?

• FDA-approved oral therapy — the first and only oral treatment approved for leishmaniasis
• WHO-recognized essential medicine — listed for neglected tropical diseases globally
• Proven clinical efficacy — high cure rates across visceral, cutaneous, and mucosal forms
• Oral capsule formulation — eliminates the need for injectable treatments and improves patient compliance
• Broad species coverage — effective against multiple Leishmania species

Important Safety Information

Miltefosine is a prescription medication requiring medical supervision. It is contraindicated in pregnancy and should not be used by women of childbearing potential without reliable contraception. Potential side effects include gastrointestinal symptoms. Always consult a qualified healthcare professional for proper diagnosis, dosing, and monitoring before starting treatment.